ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS

K. L. Raikhelson; S. N. Mehtiev

ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS

K. L. Raikhelson, S. N. Mehtiev

Full Text:

PDF (Rus)

Generate QR code

Abstract

Aim of study. To examine the possibility of adjuvant therapy in the treatment of autoimmune hepatitis. The theoretical background and the existing research on the use of hepatotropic drugs in autoimmune hepatitis have been considered. We discuss the situation when the therapy of autoimmune hepatitis can be supplemented by non-conventional medicines. It must be assumed that the treatment of autoimmune hepatitis should not always be limited to immunosuppression schemes, and in some cases may be enhanced by drugs that provide additional effects. The most promising agents for adjuvant therapy of autoimmune hepatitis are ursodeoxycholic and glycyrrhiziс acids.

Keywords

autoimmune hepatitis, treatment, glucocorticosteroids, glycyrrhizic acid, ursodeoxycholic acid

References

1. Soloway, R. D. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis / R. D. Soloway, W. Summerskill H., A. H. Baggenstoss [et al.] // Gastroenterol. - 1972. - Vol. 63., № 5. - P. 820-833.

2. Gleeson, D. British Society of Gastroenterol. (BSG) guidelines for management of autoimmune hepatitis / D. Gleeson, M. A. Heneghan, British Society of Gastroenterol. // Gut. - 2011. - Vol. 60, № 12. - P. 1611-1629.

3. EASL Clinical Practice Guidelines: Autoimmune hepatitis // J. Hepatol. - 2015. - Vol. 63. - P. 971-100.

4. Ivashkin V. T., Bueverov A. O., Maevskaya M. V., Abdulganieva D. I. Klinicheskie rekomendatsii po diagnostike i lecheniyu autoimmunnogo gepatita. / Rossiiskaya Gastroenterologicheskaya Assotsiatsiya. Rossiiskoe obshchestvo po izucheniyu pecheni 2013. URL. http://www.gastro.ru/?pageId=41. (Poslednee obrashchenie 15.08.2015).

5. EASL Clinical Practice Guidelines: Autoimmune hepatitis // J. Hepatol. - 2015. - Vol. 63. - P. 971-1004.

6. Manns, M. P. Diagnosis and management of autoimmune hepatitis / M. P. Manns, A. J. Czaja, J. D. Gorham [et al.] American Association for the Study of Liver Diseases // Hepatol. - 2010. - Vol. 51, № 6. - P. 2193-2213.

7. Czaja, A. J. Autoimmune hepatitis: focusing on treatments other than steroids. // Can J Gastroenterol. - 2012. - Vol. 26, № 9. - P. 615-620.

8. Czaja, A. J. Hepatic inflammation and progressive hepatic fibrosis in chronic liver disease. // World J Gastroenterol. - 2014. - Vol. 20, № 10. - P. 2515-2532.

9. Czaja, A. J. Difficult treatment decisions in autoimmune hepatitis. /World J. Gastroenterol. - 2010. - V. 16, N.8. - P. 934-947.

10. EASL Clinical Practice Guidelines: Wilson’s disease. // J. Hepatol. - 2012. - Vol. 56, № 3. - P. 671-685

11. Castiella, A. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. // A. Castiella, E. Zapata, M. I. Lucena, R. J. Andrade - World J. Hepatol. - 2014. - Vol. 6. № 4. - P. 160-168.

12. Czaja, A. J. Drug-induced autoimmune-like hepatitis. // Dig. Dis. Sci. - 2011. - Vol. 56. - P. 958-976.

13. Czaja, A. J. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis./ A. J. Czaja, H. A Carpenter // J. Hepatol. - 2004. - Vol. 40, № 4. - P. 646-652.

14. Mohamadnejad, M. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. / M. Mohamadnejad, R. Malekzadeh, S. Nasseri-Moghaddam [et al.] // Dig Dis Sci. - 2005. - P. 50, № 3. - P. 547-551.

15. Raikhel'son, K. L. Opyt lecheniya autoimmunnogo gepatita i ego perekrestnykh sindromov s kholestaticheskimi zabolevaniyami // K. L. Raikhel'son, N. V. Semenov, A. Yu. Baranovskii / Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta im. I. I. Mechnikova. 2013. - T. 5, № 2. - S. 80-84.

16. Szaja, A. J. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis./ A. J. Szaja, K. V. Menon, H. A. Carpenter // Hepatol. - 2002. - Vol.35, № 4. - P. 890-897

17. Abe, M. Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan. Present status of autoimmune hepatitis in Japan: a nationwide survey. / M. Abe, T. Mashiba, M. Zeniya, K. Yamamoto [et al.] // J. Gastroenterol. - 2011. - Vol.46, № 9. - P. 1136-1141.

18. Kotb, M. A. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode./ M. A. Kotb // Int. J. Mol. Sci. - 2012. - Vol.13. № 7. - P. 8882-8914.

19. Amaral, J. D. Bile acids: regulation of apoptosis by ursodeoxycholic acid / J. D Amaral., R. J. S. Viana, R. M. Ramalho [et al.] // J. Lipid. Res. - 2009 - Vol. 50, № 9. - P. 1721-1734.

20. Czaja A. J., Carpenter H. A., Lindor K. D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. / Hepatol. - 1999. - V. 30, N. 6. - P. 1381-1386.

21. Nakamura, K. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. / K. Nakmaura, M. Yoneda, S. Yokohama [et al.] // J. Gastroenterol. Hepatol. - 1998- Vol.13, N. 5., - P. 490-495.

22. Miyake Y., Iwasaki Y., Kobashi H. et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. // Hepatology Int. - 2009. - Vol.3, N. 4. - P. 556-562

23. Li, J. Y. Glycyrrhizic acid in the treatment of liver diseases: literature review / J. Y. Li, H. Y. Cao, P. Liu [et al.] / Biomed Res Int. - 2014. - 872139. [Elektronnyi resurs] URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052927

24. Tang, B. Glycyrrhizin attenuates endotoxin- induced acute liver injury after partial hepatectomy in rats. / B. Tang, H. Qiao, F. Meng, X. Sun / Braz. J. Med. Biol. Res. // 2007. - Vol.40, № 12. - P. 1637-1646.

25. Abe, M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. / M. Abe, F. Akbar, A. Hasebe [et al.] // J. Gastroenterol. - 2003. - Vol.38, № 10. - P. 962-967.

26. Tu, C-T. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. / C. - T. Tu, J. Li, F. - P. Wang [et al.] // Int. Immunopharmacol. - 2012.- Vol.14, № 4. - P. 410-421.

27. Yasui, S. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis. / S. Yasui, K. Fujiwara, A. Tawada [et al.] // Dig. Dis. Sci. - 2011. - Vol.56, № 12. - P. 3638-3647.

28. Zhixiang S. Glycyrrhizin treatment on the efficacy of autoimmune hepatitis /. C. Zhixiang, H. Weiwen, S. F. Jue / Slinical Medicine Papers. - 2011. [Elektronnyi resurs] URL. http://eng.hi138.com/medicine-papers/clinical-medicine-papers/201105/310244_glycyrrhizin-treatment-on-the-efficacy-of-autoimmune-hepatitis.asp#.Vd8NzCXtlHw.

29. Ramli, E. S. Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis. / Ramli E. S., Suhaimi F., Asri S. F. / Ramli E. S., Suhaimi F., Asri S. F. [et al.] // J. Bone Miner. Metab. - 2013. - Vol.31, № 3. - P. 262-273.

30. Sanz-Cameno, P. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. / Sanz- P. Cameno, J. Medina, L. García-Buey [et al.] // J. Hepatol. - 2002. - Vol.37, № 6. - P. 723-729.

For citations:

Raikhelson K.L., Mehtiev S.N. ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS. Experimental and Clinical Gastroenterology. 2016;(4):80-85. (In Russ.)

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1682-8658 (Print)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

Experimental and Clinical Gastroenterology

ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

User

Experimental and Clinical Gastroenterology

ADJUVANT THERAPY OF AUTOIMMUNE HEPATITIS

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy